Kathy K Byrd1, John G Hou2, Ron Hazen2, Heather Kirkham2, Sumihiro Suzuki3, Patrick G Clay4, Tim Bush1, Nasima M Camp5, Paul J Weidle1, Ambrose Delpino6. 1. Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, GA. 2. Health Analytics, Research, and Reporting Department, Walgreen Co., Deerfield, IL. 3. Department of Biostatistics and Epidemiology, University of North Texas Health Science Center, Fort Worth, TX. 4. Department of Pharmacotherapy, University of North Texas Health Science Center System College of Pharmacy, Fort Worth, TX. 5. Department of Health, Research, Informatics, and Technology, ICF, Atlanta, GA. 6. Patient Care and Advocacy Department, Walgreen Co., Deerfield, IL.
Abstract
BACKGROUND: A benchmark of near-perfect adherence (≥95%) to antiretroviral therapy (ART) is often cited as necessary for HIV viral suppression. However, given newer, more effective ART medications, the threshold for viral suppression may be lower. We estimated the minimum ART adherence level necessary to achieve viral suppression. SETTINGS: The Patient-centered HIV Care Model demonstration project. METHODS: Adherence to ART was calculated using the proportion of days covered measure for the 365-day period before each viral load test result, and grouped into 5 categories (<50%, 50% to <80%, 80% to <85%, 85% to <90%, and ≥90%). Binomial regression analyses were conducted to determine factors associated with viral suppression (HIV RNA <200 copies/mL); demographics, proportion of days covered category, and ART regimen type were explanatory variables. Generalized estimating equations with an exchangeable working correlation matrix accounted for correlation within subjects. In addition, probit regression models were used to estimate adherence levels required to achieve viral suppression in 90% of HIV viral load tests. RESULTS: The adjusted odds of viral suppression did not differ between persons with an adherence level of 80% to <85% or 85% to <90% and those with an adherence level of ≥90%. In addition, the overall estimated adherence level necessary to achieve viral suppression in 90% of viral load tests was 82% and varied by regimen type; integrase inhibitor- and nonnucleoside reverse transcriptase inhibitor-based regimens achieved 90% viral suppression with adherence levels of 75% and 78%, respectively. CONCLUSIONS: The ART adherence level necessary to reach HIV viral suppression may be lower than previously thought and may be regimen-dependent.
BACKGROUND: A benchmark of near-perfect adherence (≥95%) to antiretroviral therapy (ART) is often cited as necessary for HIV viral suppression. However, given newer, more effective ART medications, the threshold for viral suppression may be lower. We estimated the minimum ART adherence level necessary to achieve viral suppression. SETTINGS: The Patient-centered HIV Care Model demonstration project. METHODS: Adherence to ART was calculated using the proportion of days covered measure for the 365-day period before each viral load test result, and grouped into 5 categories (<50%, 50% to <80%, 80% to <85%, 85% to <90%, and ≥90%). Binomial regression analyses were conducted to determine factors associated with viral suppression (HIV RNA <200 copies/mL); demographics, proportion of days covered category, and ART regimen type were explanatory variables. Generalized estimating equations with an exchangeable working correlation matrix accounted for correlation within subjects. In addition, probit regression models were used to estimate adherence levels required to achieve viral suppression in 90% of HIV viral load tests. RESULTS: The adjusted odds of viral suppression did not differ between persons with an adherence level of 80% to <85% or 85% to <90% and those with an adherence level of ≥90%. In addition, the overall estimated adherence level necessary to achieve viral suppression in 90% of viral load tests was 82% and varied by regimen type; integrase inhibitor- and nonnucleoside reverse transcriptase inhibitor-based regimens achieved 90% viral suppression with adherence levels of 75% and 78%, respectively. CONCLUSIONS: The ART adherence level necessary to reach HIV viral suppression may be lower than previously thought and may be regimen-dependent.
Authors: Kathy K Byrd; Felicia Hardnett; Patrick G Clay; Ambrose Delpino; Ron Hazen; Michael D Shankle; Nasima M Camp; Sumihiro Suzuki; Paul J Weidle Journal: AIDS Patient Care STDS Date: 2019-01-16 Impact factor: 5.078
Authors: Jose R Castillo-Mancilla; Todd T Brown; Kristine M Erlandson; Frank J Palella; Edward M Gardner; Bernard J C Macatangay; Elizabeth C Breen; Lisa P Jacobson; Peter L Anderson; Nikolas I Wada Journal: Clin Infect Dis Date: 2016-09-22 Impact factor: 9.079
Authors: M Martin; E Del Cacho; C Codina; M Tuset; E De Lazzari; J Mallolas; J-M Miró; J M Gatell; J Ribas Journal: AIDS Res Hum Retroviruses Date: 2008-10 Impact factor: 2.205
Authors: Myron S Cohen; Ying Q Chen; Marybeth McCauley; Theresa Gamble; Mina C Hosseinipour; Nagalingeswaran Kumarasamy; James G Hakim; Johnstone Kumwenda; Beatriz Grinsztejn; Jose H S Pilotto; Sheela V Godbole; Suwat Chariyalertsak; Breno R Santos; Kenneth H Mayer; Irving F Hoffman; Susan H Eshleman; Estelle Piwowar-Manning; Leslie Cottle; Xinyi C Zhang; Joseph Makhema; Lisa A Mills; Ravindre Panchia; Sharlaa Faesen; Joseph Eron; Joel Gallant; Diane Havlir; Susan Swindells; Vanessa Elharrar; David Burns; Taha E Taha; Karin Nielsen-Saines; David D Celentano; Max Essex; Sarah E Hudelson; Andrew D Redd; Thomas R Fleming Journal: N Engl J Med Date: 2016-07-18 Impact factor: 91.245
Authors: Zara Shubber; Edward J Mills; Jean B Nachega; Rachel Vreeman; Marcelo Freitas; Peter Bock; Sabin Nsanzimana; Martina Penazzato; Tsitsi Appolo; Meg Doherty; Nathan Ford Journal: PLoS Med Date: 2016-11-29 Impact factor: 11.069
Authors: Elizabeth Whalley Buono; Bernard Vrijens; Hayden B Bosworth; Larry Z Liu; Leah L Zullig; Bradi B Granger Journal: Patient Prefer Adherence Date: 2017-06-02 Impact factor: 2.711
Authors: David W Pantalone; Kimberly M Nelson; Abigail W Batchelder; Christopher Chiu; Hamish A Gunn; Keith J Horvath Journal: J Sex Res Date: 2020-02-20
Authors: Laura B Whiteley; Elizabeth M Olsen; Kayla K Haubrick; Enyonam Odoom; Nicholas Tarantino; Larry K Brown Journal: Curr HIV/AIDS Rep Date: 2021-06-21 Impact factor: 5.071
Authors: Asante R Kamkwalala; Ankita Garg; Upal Roy; Avery Matthews; Jose Castillo-Mancilla; Jordan E Lake; Giada Sebastiani; Michael Yin; Todd T Brown; Angela R Kamer; Douglas A Jabs; Ronald J Ellis; Marta Boffito; Meredith Greene; Sarah Schmalzle; Eugenia Siegler; Kristine M Erlandson; David J Moore Journal: AIDS Res Hum Retroviruses Date: 2021-09-20 Impact factor: 2.205
Authors: Michela Blain; Barbra A Richardson; John Kinuthia; Danielle N Poole; Walter Jaoko; Kate S Wilson; Anne Kaggiah; Jane M Simoni; Carey Farquhar; R Scott McClelland Journal: AIDS Behav Date: 2020-12
Authors: Seth C Kalichman; Harold Katner; Ellen Banas; Marnie Hill; Moira O Kalichman Journal: AIDS Patient Care STDS Date: 2020-11 Impact factor: 5.078
Authors: Nicole Y Frascino; Jessie K Edwards; Michael E Herce; Joanna Maselko; Audrey E Pettifor; Nyanyiwe Mbeye; Sharon S Weir; Brian W Pence Journal: AIDS Behav Date: 2021-05-13
Authors: Seth C Kalichman; Harold Katner; Lisa A Eaton; Ellen Banas; Marnie Hill; Moira O Kalichman Journal: Transl Behav Med Date: 2021-04-07 Impact factor: 3.046
Authors: Rachel Brathwaite; Fred M Ssewamala; Torsten B Neilands; Moses Okumu; Massy Mutumba; Christopher Damulira; Proscovia Nabunya; Samuel Kizito; Ozge Sensoy Bahar; Claude A Mellins; Mary M McKay Journal: J Int AIDS Soc Date: 2021-06 Impact factor: 6.707